<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">OTO Open</journal-id><journal-id journal-id-type="iso-abbrev">OTO Open</journal-id><journal-id journal-id-type="publisher-id">OPN</journal-id><journal-id journal-id-type="hwp">spopn</journal-id><journal-title-group><journal-title>OTO Open</journal-title></journal-title-group><issn pub-type="epub">2473-974X</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6239026</article-id><article-id pub-id-type="doi">10.1177/2473974X18761868</article-id><article-id pub-id-type="publisher-id">10.1177_2473974X18761868</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Head and Neck Squamous Cell Carcinoma in Western Uganda: Disease of
Uncertainty and Poor Prognosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nabukenya</surname><given-names>Jamilah</given-names></name><degrees>MMed</degrees><xref ref-type="aff" rid="aff1-2473974X18761868">1</xref><xref ref-type="corresp" rid="corresp1-2473974X18761868"/></contrib><contrib contrib-type="author"><name><surname>Hadlock</surname><given-names>Tessa A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2-2473974X18761868">2</xref></contrib><contrib contrib-type="author"><name><surname>Arubaku</surname><given-names>Wilfred</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="aff3-2473974X18761868">3</xref></contrib></contrib-group><aff id="aff1-2473974X18761868"><label>1</label>Ear, Nose and Throat Department, Mbarara
University of Science and Technology, Mbarara, Uganda</aff><aff id="aff2-2473974X18761868"><label>2</label>Massecheutts Ear and Eye Infirmary,
Boston, Massachusetts, USA</aff><aff id="aff3-2473974X18761868"><label>3</label>Dental and Oral Surgery Department,
Mbarara University of Science and Technology, Mbarara, Uganda</aff><author-notes><corresp id="corresp1-2473974X18761868">Jamilah Nabukenya, MMed, Ear, Nose and
Throat Department, Mbarara University of Science and Technology, Plot 8 Mbarara,
Mbarara, 256, Uganda. Email: <email>jnabukenya@must.ac.ug</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><season>Jan-Mar</season><year>2018</year></pub-date><volume>2</volume><issue>1</issue><elocation-id>2473974X18761868</elocation-id><history><date date-type="received"><day>3</day><month>1</month><year>2018</year></date><date date-type="rev-recd"><day>29</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>7</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Authors 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder content-type="society">American Academy of Otolaryngology - Head
and Neck Surgery Foundation, unless otherwise noted. Manuscript content on this
site is licensed under Creative Commons Licenses.</copyright-holder><license license-type="creative-commons" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec id="section1-2473974X18761868"><title>Objectives</title><p>Patients with head and neck squamous cell carcinoma (HNSCC) have symptoms
that masquerade as benign conditions, resulting in late presentations. The
objective is to describe characteristics and stages of patients with HNSCC
and document their prognosis from clinical experience in western Uganda.</p></sec><sec id="section2-2473974X18761868"><title>Study Design</title><p>Cross-sectional study with clinical follow-up.</p></sec><sec id="section3-2473974X18761868"><title>Setting</title><p>Mbarara Regional Referral Hospital.</p></sec><sec id="section4-2473974X18761868"><title>Subjects and Methods</title><p>Fifty-one participants were recruited from February to July 2016. A
questionnaire was used for patient characteristics, and staging, serologic
studies, biopsy for histopathology, and immunohistochemistry were
investigated. Staging was subclassified as early (stage I and II) and late
(stage III and IV). Analysis was done with Fisher&#x02019;s exact test.</p></sec><sec id="section5-2473974X18761868"><title>Results</title><p>Of 51 participants, 44 (86.5%) were male; the group had a mean age of 57.7
years, and 41 (80.1%) presented with late stage. Of 10 participants who
presented with early stage, 6 (60%) had laryngeal HNSCC. The pharynx was
ranked as the highest subsite (n = 19, 37.3%), followed by the oral cavity
(n = 9, 17.6%), the larynx (n = 9, 17.6%), an unknown primary (n = 8,
15.7%), and sinonasal area (n = 6, 11.8%). Tobacco smoking, alcohol
consumption, and prior use of traditional remedy were common characteristics
among participants. Moderate differentiation was the most common grade (n =
23, 45.1%). <italic>Helicobacter pylori</italic>, Epstein-Barr virus, human
immunodeficiency virus, and human papilloma virus type 16 were identified
among 51 participants. However, none could afford referral for radiotherapy;
hence, 1-year survival was 4%.</p></sec><sec id="section6-2473974X18761868"><title>Conclusion</title><p>The majority of our patients with HNSCC present at late stage, and the
prognosis is poor. There is great need for preventative community-based
education and early screening services to save our population.</p></sec></abstract><kwd-group><kwd>head and neck squamous cell carcinoma</kwd><kwd>Uganda</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-March 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Head and neck squamous cell carcinoma (HNSCC) is the sixth-most common type of cancer
affecting the upper digestive tract, representing approximately 6% of all new cancer cases.<sup><xref rid="bibr1-2473974X18761868" ref-type="bibr">1</xref></sup> HNSCC is thought to account for 350,000 cancer deaths worldwide per year, with
males affected significantly more than females at a ratio of 4:1.<sup><xref rid="bibr2-2473974X18761868" ref-type="bibr">2</xref></sup> Reliable data from Africa are absent, and most information is from hospital-based
registries or case series, as opposed to population-based data.<sup><xref rid="bibr2-2473974X18761868" ref-type="bibr">2</xref></sup> The few available reports provide data from Nigeria,<sup><xref rid="bibr3-2473974X18761868" ref-type="bibr">3</xref></sup> Egypt,<sup><xref rid="bibr4-2473974X18761868" ref-type="bibr">4</xref></sup> and Kenya.<sup><xref rid="bibr5-2473974X18761868" ref-type="bibr">5</xref></sup> A Ugandan report indicated that between 1989 and 1999 at Mulago Hospital, 1298
neoplastic orofacial cases were identified in by oromaxillofacial department, of which
15% were HNSCC.<sup><xref rid="bibr6-2473974X18761868" ref-type="bibr">6</xref></sup> In addition, 16% of 1292 patients treated in the radiation department with
Chinese GWGP80 cobalt unit had HNSCC.<sup><xref rid="bibr7-2473974X18761868" ref-type="bibr">7</xref></sup></p><p>Despite advances in diagnostic tools and treatment modalities, almost two-thirds of
patients with HNSCC present with advanced disease (stages III and IV).<sup><xref rid="bibr8-2473974X18761868" ref-type="bibr">8</xref></sup> In the early stages of the disease (I and II), patients with HNSCC have a 5-year
survival rate of 70% to 90%, independent of the sublocation or treatment.<sup><xref rid="bibr9-2473974X18761868" ref-type="bibr">9</xref></sup> In contrast, in advanced stages of the disease, patients display different
survival rates, depending on the tumor.</p><p>In Uganda, the incidence of cancers has been on the rise over the past 20
years,<sup><xref rid="bibr10-2473974X18761868" ref-type="bibr">10</xref>,<xref rid="bibr11-2473974X18761868" ref-type="bibr">11</xref></sup> and it appears
that patients present with late disease. A report from Kampala covering the time frame
2004 to 2009 reported that 219 patients had HNSCC, of which 56.2% had lymph node
involvement and 6.8% had distant metastases at diagnosis.<sup><xref rid="bibr12-2473974X18761868" ref-type="bibr">12</xref>,<xref rid="bibr13-2473974X18761868" ref-type="bibr">13</xref></sup></p><p>We aimed to describe the characteristics and stages of patients with HNSCC and document
their prognosis from clinical experience in a rural setting in western Uganda.</p><sec sec-type="methods" id="section7-2473974X18761868"><title>Methods</title><p>We conducted a cross-sectional study with clinical follow-up of patients with HNSCC
at Mbarara Regional Referral Hospital in the outpatient departments of the ENT (ear,
nose, and throat), surgery, and dental clinics. Patients with suspected HNSCC were
consecutively recruited between February 2016 and July 2016 for a total of 54
cases.</p><p>A questionnaire captured patient demographics, socioeconomic characteristics, and
presenting complaint. Complete clinical examination and flexible
nasopharyngolaryngoscopy were performed, and patients were staged through the
American Joint Committee on Cancer staging system (tumor, node, and metastasis
[TNM]).</p><p>Biopsies were later taken for histology from all participants with suspected HNSCC.
Routine hematoxylin and eosin staining was used to confirm diagnosis and typing of
tissues into well, moderately, and poorly differentiated carcinoma. Additionally,
lymphagiovascular permeation and perineural invasion assessment were performed, and
P16 immunohistochemistry was done to determine the human papilloma virus (HPV)
status of the biopsies.</p><p>Participants underwent chest radiography for assessment of lung metastases. Routine
blood investigations for human immunodeficiency virus (HIV), <italic>Helicobacter
pylori</italic>, and Epstein-Barr virus were performed for each participant.</p><p>The study was approved by the Research Ethics Committee at the Mbarara University of
Science and Technology. Anonymity and confidentiality were ensured by identification
numbers on questionnaires (ie, no names or initials). Participants&#x02019; identities were
known only to the principal investigator, who was their primary health care
provider. Written informed consent was obtained from the participants with suspected
HNSCC. Privacy was ensured during the interviews.</p><sec id="section8-2473974X18761868"><title>Data Analysis</title><p>A total of 54 participants were recruited to participate in study; of these, 3
were excluded per their histology results, which included rhabdomyosarcoma,
basal cell carcinoma, and adenocystic carcinoma. Data from completed
questionnaires were entered into Microsoft Excel 2007 and exported to STATA/IC
13.0 (StataCorp LLC, College Station, Texas) for analysis.</p><p>The dependent variable was stage. The following independent variables were
assessed for their confounding effects on stage: demographics (age, sex, income,
occupation), socioeconomic characteristics (smoking status, alcohol status,
marital status, family history of cancer), and serologic and histologic
characteristics (HPV, HIV, Epstein-Barr virus, <italic>H pylori</italic>, and
histology types).</p><p>Age was grouped into &#x0003c;55 or &#x02265;55 years, based on the 2016 Uganda demographic
profile, which stated that the total population life expectancy in Uganda is
55.4 years. Income was categorized as &#x02265;144,100 and &#x0003c;144,100 Uganda shillings
(about US $40). This was adapted from the Uganda Bureau of Statistics, which
stated that the 2016 average household monthly income is 144,100 Uganda
shillings in rural setting. Staging of HNSCC was subclassified as early (stage I
and II) and late (stage III and IV).</p><p>For the descriptive statistics, we used chi-square analysis and adjusted for the
Fisher&#x02019;s exact method in univariate analysis, with data represented in tables
and graphs. A significance level of <italic>P</italic> &#x02264; .05 was used.</p></sec></sec><sec sec-type="results" id="section9-2473974X18761868"><title>Results</title><p>From February to July 2016, 51 participants with confirmed HNSCC at Mbarara Regional
Referral Hospital were enrolled into the study. The majority (n = 42, 82.4%) were
peasant farmers with a diet composed of plantain (locally referred to as
<italic>matooke</italic>), millet bread, maize flour, beans, green vegetables,
and occasional meat without spices and oils; they had no prior exposure to
radiotherapy; and they were na&#x000ef;ve of oral sexual practices.</p><p><xref rid="table1-2473974X18761868" ref-type="table">
<bold>Table 1</bold>
</xref> presents the sociodemographic characteristics of all study participants. The
mean age was 57.7 years; 39 participants were &#x02265;55 years old; and the lowest limit
was 20 years. The group had a male:female ratio of 6:1. The majority of the
participants earned &#x0003c;144,100 Uganda shillings annually. Among the participants,
42 (82.4%) had a history of tobacco smoking and alcohol intake, and 5 (9.8%) had a
family history of aerodigestive cancers.</p><table-wrap id="table1-2473974X18761868" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Demographic and Socioeconomic Characteristics of 51 Patients Aged 20 to 90
Years with Head and Neck Squamous Cell Carcinoma.</p></caption><alternatives><graphic xlink:href="10.1177_2473974X18761868-table1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">Mean &#x000b1; SD or n (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, y</td><td rowspan="1" colspan="1">57.7 &#x000b1; 14.0</td></tr><tr><td rowspan="1" colspan="1">Age category, y</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;55</td><td rowspan="1" colspan="1">12 (23.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02265;55</td><td rowspan="1" colspan="1">39 (76.5)</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Female</td><td rowspan="1" colspan="1">7 (13.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Male</td><td rowspan="1" colspan="1">44 (86.5)</td></tr><tr><td rowspan="1" colspan="1">Monthly income, Uganda shillings</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;144,100</td><td rowspan="1" colspan="1">33 (64.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02265;144,100</td><td rowspan="1" colspan="1">18 (35.3)</td></tr><tr><td rowspan="1" colspan="1">Level of education</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;None</td><td rowspan="1" colspan="1">15 (29.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Primary</td><td rowspan="1" colspan="1">28 (54.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Secondary</td><td rowspan="1" colspan="1">4 (7.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Tertiary</td><td rowspan="1" colspan="1">4 (7.6)</td></tr><tr><td rowspan="1" colspan="1">Occupation</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Manual laborer</td><td rowspan="1" colspan="1">3 (5.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Professional</td><td rowspan="1" colspan="1">3 (5.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Business</td><td rowspan="1" colspan="1">3 (5.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Peasant</td><td rowspan="1" colspan="1">42 (82.4)</td></tr><tr><td rowspan="1" colspan="1">Ever smoked tobacco</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">9 (17.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">42 (82.4)</td></tr><tr><td rowspan="1" colspan="1">Ever taken alcohol</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">10 (19.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">41 (80.4)</td></tr><tr><td rowspan="1" colspan="1">Family history of cancer</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">46 (90.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">5 (9.8)</td></tr><tr><td rowspan="1" colspan="1">Duration of symptoms to presentation, mo</td><td rowspan="1" colspan="1">11.4 &#x000b1; 10.4</td></tr></tbody></table></alternatives></table-wrap><p><xref rid="table2-2473974X18761868" ref-type="table">
<bold>Table 2</bold>
</xref> and <xref ref-type="fig" rid="fig1-2473974X18761868">
<bold>Figure 1</bold>
</xref> illustrate that among the participants in the study, 41 (80.1%) presented
with late stage according to the American Joint Committee on Cancer staging
system.</p><table-wrap id="table2-2473974X18761868" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Distribution of Stage and AJCC Classification for 51 Participants with HNSCC
Seen at the Mbarara Regional Referral Hospital (February-August 2016).</p></caption><alternatives><graphic xlink:href="10.1177_2473974X18761868-table2"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="5" rowspan="1">Participants, n (%)<hr/></th><th rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">AJCC</th><th align="center" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Stage 1</th><th align="center" rowspan="1" colspan="1">Stage 2</th><th align="center" rowspan="1" colspan="1">Stage 3</th><th align="center" rowspan="1" colspan="1">Stage 4</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Tumor</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.0001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;1</td><td rowspan="1" colspan="1">4 (9.1)</td><td rowspan="1" colspan="1">4 (100.0)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;2</td><td rowspan="1" colspan="1">7 (15.9)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">6 (100.0)</td><td rowspan="1" colspan="1">1 (25.0)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;3</td><td rowspan="1" colspan="1">5 (11.4)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2 (50.0)</td><td rowspan="1" colspan="1">3 (10.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;4</td><td rowspan="1" colspan="1">28 (63.6)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (25.0)</td><td rowspan="1" colspan="1">27 (90.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Nodal</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.0001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;0</td><td rowspan="1" colspan="1">17 (33.3)</td><td rowspan="1" colspan="1">4 (100.0)</td><td rowspan="1" colspan="1">6 (100.0)</td><td rowspan="1" colspan="1">2 (50.0)</td><td rowspan="1" colspan="1">5 (13.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;1</td><td rowspan="1" colspan="1">4 (7.8)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (25.0)</td><td rowspan="1" colspan="1">3 (8.1)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;2</td><td rowspan="1" colspan="1">14 (27.5)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (25.0)</td><td rowspan="1" colspan="1">13 (35.1)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;3</td><td rowspan="1" colspan="1">16 (31.4)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">16 (43.2)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Metastases</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.0001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;0</td><td rowspan="1" colspan="1">44 (86.3)</td><td rowspan="1" colspan="1">4 (100.0)</td><td rowspan="1" colspan="1">6 (100.0)</td><td rowspan="1" colspan="1">4 (100.0)</td><td rowspan="1" colspan="1">30 (100.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;1</td><td rowspan="1" colspan="1">7 (13.7)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-2473974X18761868"><p>Abbreviations: AJCC, American Joint Committee on Cancer; HNSCC, head and
neck squamous cell carcinoma.</p></fn></table-wrap-foot></table-wrap><fig id="fig1-2473974X18761868" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Clinical stage distribution among 51 study participants with head and neck
squamous cell carcinoma.</p></caption><graphic xlink:href="10.1177_2473974X18761868-fig1"/></fig><p>Of 10 patients who presented in early stage, 6 (60%) had laryngeal HNSCC. Pharynx
ranked highest for HNSCC subsite (n = 19, 37.3%), followed by the oral cavity (n =
9, 17.6%), the larynx (n = 9, 17.6%), an unknown primary (n = 8, 15.7%), and
sinonasal area (n = 6, 11.8%), as shown in <xref ref-type="fig" rid="fig2-2473974X18761868">
<bold>Figure 2</bold>
</xref>.</p><fig id="fig2-2473974X18761868" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Number of participants distributed across head and neck squamous cell
carcinoma sites by clinical stage at presentation (N = 51).</p></caption><graphic xlink:href="10.1177_2473974X18761868-fig2"/></fig><sec id="section10-2473974X18761868"><title>Patient Characteristics</title><p>The majority of patients who presented with late-stage disease were aged &#x02265;55
years (n = 30, 73.2%), were men (n = 36, 87.8%), and earned &#x0003c;144,100 Uganda
shillings (n = 26, 63.4%). Among them, 33 (80.5%) had no education or a primary
level of education; 32 (78.1%) were peasant farmers; and 33 (80.5%) admitted to
use of traditional remedy (<italic>Bishaka</italic> in the local language) for
different traditional diagnoses (<italic>enfumbi</italic> and
<italic>ebinyoro</italic> in local language) prior to presentation to the
hospital. Among those presenting with late-stage disease, 32 (78.1%) and 31
(75.6%) had a history of tobacco smoking and alcohol intake, respectively (<xref rid="table3-2473974X18761868" ref-type="table">
<bold>Table 3</bold>
</xref>).</p><table-wrap id="table3-2473974X18761868" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Demographic and Socioeconomic Characteristics in Relation to Stage for 51
Participants with Head and Neck Squamous Cell Carcinoma.</p></caption><alternatives><graphic xlink:href="10.1177_2473974X18761868-table3"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Participants, n (%)<hr/></th><th rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Demographic/Socioeconomic</th><th align="center" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Early Stage</th><th align="center" rowspan="1" colspan="1">Late Stage</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, y</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.261</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;55</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">1 (10.0)</td><td rowspan="1" colspan="1">11 (26.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02265;55</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">9 (90.0)</td><td rowspan="1" colspan="1">30 (73.2)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.520</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">2 (20.0)</td><td rowspan="1" colspan="1">5 (12.2)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Male</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">8 (80.0)</td><td rowspan="1" colspan="1">36 (87.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Income, Uganda shillings</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.1527</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;144,100</td><td rowspan="1" colspan="1">33 (100)</td><td rowspan="1" colspan="1">7 (70.0)</td><td rowspan="1" colspan="1">26 (63.4)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02265;144,100</td><td rowspan="1" colspan="1">18 (100.0)</td><td rowspan="1" colspan="1">3 (30.0)</td><td rowspan="1" colspan="1">15 (36.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Level of education</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;None</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">4 (40.0)</td><td rowspan="1" colspan="1">11 (26.8)</td><td rowspan="1" colspan="1">.289</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Primary</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">6 (60.0)</td><td rowspan="1" colspan="1">22 (53.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Secondary/tertiary</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">8 (19.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Occupation</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Manual laborer</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (7.3)</td><td rowspan="1" colspan="1">.446</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Professional</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (7.3)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Business</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (7.3)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Peasant</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">10 (100.0)</td><td rowspan="1" colspan="1">32 (78.1)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Ever smoked tobacco</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.103</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">9 (21.9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">10 (100.0)</td><td rowspan="1" colspan="1">32 (78.1)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Ever taken alcohol</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">10 (24.4)</td><td rowspan="1" colspan="1">.082</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">10 (100.0)</td><td rowspan="1" colspan="1">31 (75.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Use of traditional/herbal remedy prior</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.128</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">8 (19.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">10 (100.0)</td><td rowspan="1" colspan="1">33 (80.5)</td><td rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></sec><sec id="section11-2473974X18761868"><title>Serologic and Histologic Characteristics in Relation to Stage</title><p>Among all the participants who tested positive for HIV, 6 presented with late
clinical stage; however, <italic>H pylori</italic> tested positive for 30
participants, of whom 24 presented with late stage. Epstein-Barr virus
immunoglobulin M tested positive for 4 participants. These participants had
nasopharyngeal keratinizing carcinoma, of which 3 presented with late stage,
including the youngest participant in the study (a 20-year-old man).</p><p>Histologically, there was a proportional distribution of squamous cell cancer
differentiation: well (n = 9, 22.0%), moderate (n = 20, 48.8%), and poorly (n =
12, 29.2%). Of the 51 participants, only 6 were positive for HPV type 16 on P16
immunohistochemistry. Among the 5 who presented with late stage, their lesions
were oropharyngeal in origin, whereas the participant who presented with early
stage had a laryngeal lesion. Regarding histology, keratinization was present in
28 biopsies, of which 26 were among participants with late-stage disease (<xref rid="table4-2473974X18761868" ref-type="table">
<bold>Table 4</bold>
</xref>).</p><table-wrap id="table4-2473974X18761868" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Serologic and Histologic Characteristics in Relation to Stage for 51
Participants with Head and Neck Squamous Cell Carcinoma.</p></caption><alternatives><graphic xlink:href="10.1177_2473974X18761868-table4"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Participants, n (%)<hr/></th><th rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Serologic-Histologic</th><th align="center" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Early Stage</th><th align="center" rowspan="1" colspan="1">Late Stage</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Human immunodeficiency virus</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.6585</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Negative</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">10 (100.0)</td><td rowspan="1" colspan="1">35 (85.4)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Positive</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">6 (14.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>Helicobacter pylori</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.0071</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Negative</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">4 (40.0)</td><td rowspan="1" colspan="1">17 (41.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Positive</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">6 (60.0)</td><td rowspan="1" colspan="1">24 (58.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Epstein-Barr virus immunoglobulin M</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Negative</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">9 (90.0)</td><td rowspan="1" colspan="1">38 (92.7)</td><td rowspan="1" colspan="1">.0801</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Positive</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1 (10.0)</td><td rowspan="1" colspan="1">3 (7.3)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">P16 (human papilloma virus)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.0373</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Negative</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">9 (90.0)</td><td rowspan="1" colspan="1">36 (87.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Positive</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">1 (10.0)</td><td rowspan="1" colspan="1">5 (12.2)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Squamous cell carcinoma differentiation</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.093</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Well</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">6 (60.0)</td><td rowspan="1" colspan="1">9 (22.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Moderate</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">3 (30.0)</td><td rowspan="1" colspan="1">20 (48.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Poor</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">1 (10.0)</td><td rowspan="1" colspan="1">12 (29.2)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Squamous cell carcinoma keratinizing type</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.030</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">8 (80.0)</td><td rowspan="1" colspan="1">15 (36.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">2 (20.0)</td><td rowspan="1" colspan="1">26 (63.4)</td><td rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap><p>Among the 51 participants, none were able to afford referral to the neighboring
country for radiotherapy; hence, the 1-year survival rate was 4%.</p></sec></sec><sec sec-type="discussion" id="section12-2473974X18761868"><title>Discussion</title><p>The diagnosis of HNSCC in western Uganda takes a turmoil on both caregiver and
patient. As the world advances in diagnostic tools and treatment modalities, HNSCC
remains a major source of morbidity and mortality, with almost two-thirds of
patients with HNSCC presenting with advanced disease (stages III and IV).<sup><xref rid="bibr14-2473974X18761868" ref-type="bibr">14</xref></sup> In Africa, published clinical experience at Kenyatta National Hospital showed
that most patients presented with late disease, and this is a setting where variable treatment<sup><xref rid="bibr15-2473974X18761868" ref-type="bibr">15</xref></sup> options and countrywide screening programs are in place. Our study showed
that 80.1% of patients with HNSCC presented with late stage. These results also
indicate that more participants in western Uganda presented with late stage as
compared with other patient populations with oropharyngeal cancer, who have
documented rates of 60% and 77%.<sup><xref rid="bibr16-2473974X18761868" ref-type="bibr">16</xref>,<xref rid="bibr17-2473974X18761868" ref-type="bibr">17</xref></sup></p><p>The American Joint Committee on Cancer TNM staging system was applicable and readily
adapted in our setting. Among patients who had tumor stage 4 at presentation, 80%
had late stage, and 31.4% had nodal spread on clinical examination. There was
statistical significance between TNM staging and stage. However, assessment of
participants with metastatic neck lymph nodes with an unknown primary was a
challenge per financial constraints, despite flexible nasopharyngolaryngoscopy and
bimanual palpation.</p><p>We also found a statistically significant relationship between stage at presentation
and site of the tumor. The majority of the patients who presented with late stage
had HNSCC lesions in the oral cavity and pharynx (50.7%); however, an additional
15.6% of participants with an unknown primary brought this percentage to 66.3%.
Participants who presented with early stage mostly had HNSCC in the larynx. In our
study, laryngeal involvement resulted in difficulty in breathing, prompting patients
to present earlier than those with HNSCC in other sites. These findings are similar
to research conducted in India, where patients who presented in early stage had
laryngeal HNSCC.<sup><xref rid="bibr18-2473974X18761868" ref-type="bibr">18</xref></sup></p><p>For age in general, our results are also similar to research conducted in India,<sup><xref rid="bibr18-2473974X18761868" ref-type="bibr">18</xref></sup> where the age range was 25 to 85 years, although we differ by having an age
range of 20 to 90 years with a mean (SD) of 57.7 (14.0) years. The participant with
the lowest age was a 20-year-old man with nasopharyngeal carcinoma, who tested
positive for Epstein-Barr virus immunoglobulin M and negative for P16, while the
oldest participant was a 90-year-old man with metastatic neck lymph nodes and an
unknown primary.</p><p>Participants whose socioeconomic characteristics included being a peasant farmer, low
income, and low educational status were more inclined to present with late-stage
disease. Thus, patients with low socioeconomic status are more likely to present
with late stage, and more attention ought to be paid to them as a vulnerable population.<sup><xref rid="bibr19-2473974X18761868" ref-type="bibr">19</xref></sup></p><p>Use of traditional/herbal remedy prior to presentation to the hospital was reported
among 84.3% of participants, with a mean of 11.4 months from experience of the first
symptom to hospital presentation. Traditional herbalists in western Uganda are
affordable and easy to access, and they understand cultural beliefs. Although they
play a role in delay in hospital presentation, the pharmacokinetics of traditional
herbal medicine in the diagnosis and management of HNSCC are still unknown.</p><p>Our study demonstrated that the majority of patients with HNSCC had a history of
tobacco smoking and alcohol intake, and a few were positive for HIV, Epstein-Barr
virus, <italic>H pylori</italic>, and HPV subtype 16. These are established risk
factors for HNSCC. However, our study also reveals the shortage of countrywide
preventative and early screening interventions for HNSCC in Uganda.</p><p>According to a recent National Cancer Database report, approximately 822,000 cancers
of the head and neck are HNSCC. Histological typing in our study showed 20 (82.6%)
participants with moderately differentiated HNSCC and 12 (84.6%) with poorly
differentiated HNSCC presenting with late stage (<italic>P</italic> = .03; likewise
for keratinization). As recently shown, biological tumor behavior may be independent
of anatomic staging, and keratinizing HNSCC lesions may be more aggressive in
nature; as such, knowledge of a given squamous cell carcinoma tumor&#x02019;s grade remains
a critical factor in the construction of an accurate prognosis.<sup><xref rid="bibr20-2473974X18761868" ref-type="bibr">20</xref></sup> Among the 51 participants, none were able to afford referral to the
neighboring country for radiotherapy, and the 1-year survival rate was 4% from
clinical experience.</p><sec id="section13-2473974X18761868"><title>Limitations</title><p>Genetic assays would have added information on risk factors for HNSCC; however,
this was not done because of financial constraints.</p></sec></sec><sec sec-type="conclusions" id="section14-2473974X18761868"><title>Conclusion</title><p>The majority of our patients with HNSCC present with late stage, and the prognosis is
poor. There is a need for preventative community-based education and early screening
services to save our population.</p></sec><sec id="section15-2473974X18761868"><title>Author Contributions</title><p><bold>Jamilah Nabukenya</bold>, conceived the study and participated in data
collection and analysis and manuscript writing; <bold>Tessa A. Hadlock</bold>,
participated conceptualization of the topic, manuscript revision, and writing
guidance; <bold>Wilfred Arubaku</bold>, supervisor and guided in proposal
development and manuscript preparation proofreading.</p></sec><sec id="section16-2473974X18761868"><title>Disclosures</title><p content-type="COI-statement"><bold>Competing interests:</bold> None.</p><p><bold>Sponsorships:</bold> None.</p><p><bold>Funding source:</bold> Swedish International Developmental Agency and Mbarara
University of Science and Technology provided the funds for data collection.</p></sec></body><back><ack><p>We acknowledge the Ear, Nose, and Throat Department and the Oncology Department at
Mbarara University of Science and Technology and the Mbarara Regional Referral
Hospital laboratory staff, with special thanks to Max Irama and the Lancet
Laboratories community. Finally, to all the patients and their caregivers who
participated in the study, we are truly grateful.</p></ack><fn-group><fn><p>Sponsorships or competing interests that may be relevant to content are disclosed
at the end of this article.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-2473974X18761868"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>HR</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Parkin</surname><given-names>DM.</given-names></name></person-group>
<article-title>Estimates of worldwide burden of cancer in 2008: GLOBOCAN
2008</article-title>. <source>Int J Cancer</source>.
<year>2010</year>;<volume>127</volume>:<fpage>2893</fpage>-<lpage>2917</lpage>.<pub-id pub-id-type="pmid">21351269</pub-id></mixed-citation></ref><ref id="bibr2-2473974X18761868"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P.</given-names></name></person-group>
<article-title>Estimating the world cancer burden: GLOBOCAN
2000</article-title>. <source>Int J Cancer</source>.
<year>2001</year>;<volume>94</volume>:<fpage>153</fpage>-<lpage>156</lpage>.<pub-id pub-id-type="pmid">11668491</pub-id></mixed-citation></ref><ref id="bibr3-2473974X18761868"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ologe</surname><given-names>FE</given-names></name><name><surname>Adeniji</surname><given-names>KA</given-names></name><name><surname>Segun-Busari</surname><given-names>S.</given-names></name></person-group>
<article-title>Clinicopathological study of head and neck cancers in Ilorin,
Nigeria</article-title>. <source>Trop Doct</source>.
<year>2005</year>;<volume>35</volume>:<fpage>2</fpage>-<lpage>4</lpage>.<pub-id pub-id-type="pmid">15712528</pub-id></mixed-citation></ref><ref id="bibr4-2473974X18761868"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Attar</surname><given-names>E</given-names></name><name><surname>Dey</surname><given-names>S</given-names></name><name><surname>Hablas</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Head and neck cancer in a developing country: a
population-based perspective across 8 years</article-title>. <source>Oral
Oncol</source>.
<year>2010</year>;<volume>46</volume>:<fpage>591</fpage>-<lpage>596</lpage>.<pub-id pub-id-type="pmid">20619719</pub-id></mixed-citation></ref><ref id="bibr5-2473974X18761868"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gathere</surname><given-names>S</given-names></name><name><surname>Mutuma</surname><given-names>G</given-names></name><name><surname>Korir</surname><given-names>A</given-names></name><name><surname>Musibi</surname><given-names>A.</given-names></name></person-group>
<article-title>Head and neck cancers four year trend at the Nairobi Cancer
Registry</article-title>. <source>Afr J Health Sci</source>.
<year>2011</year>;<volume>19</volume>:<fpage>30</fpage>-<lpage>35</lpage>.</mixed-citation></ref><ref id="bibr6-2473974X18761868"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kamulegeya</surname><given-names>A</given-names></name><name><surname>Kalyanyama</surname><given-names>BM.</given-names></name></person-group>
<article-title>Oral maxillofacial neoplasms in an East African population a 10
year retrospective study of 1863 cases using histopathological
reports</article-title>. <source>BMC Oral Health</source>.
<year>2008</year>;<volume>8</volume>:<fpage>19</fpage>.<pub-id pub-id-type="pmid">18651958</pub-id></mixed-citation></ref><ref id="bibr7-2473974X18761868"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kigula Mugambe</surname><given-names>JB</given-names></name><name><surname>Wegoye</surname><given-names>P.</given-names></name></person-group>
<article-title>Pattern and experience with cancers treated with the Chinese
GWCP80 cobalt unit at Mulago Hospital, Kampala</article-title>. <source>East
Afr Med J</source>.
<year>2000</year>;<volume>77</volume>:<fpage>523</fpage>-<lpage>525</lpage>.<pub-id pub-id-type="pmid">12862117</pub-id></mixed-citation></ref><ref id="bibr8-2473974X18761868"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duray</surname><given-names>A</given-names></name><name><surname>Demoulin</surname><given-names>S</given-names></name><name><surname>Hubert</surname><given-names>P</given-names></name><name><surname>Delvenne</surname><given-names>P</given-names></name><name><surname>Saussez</surname><given-names>S.</given-names></name></person-group>
<article-title>Immune suppression in head and neck cancers: a
review</article-title>. <source>Clin Dev Immunol</source>.
<year>2010</year>;<volume>2010</volume>:<fpage>701657</fpage>.<pub-id pub-id-type="pmid">21437225</pub-id></mixed-citation></ref><ref id="bibr9-2473974X18761868"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Forastiere</surname><given-names>AA</given-names></name><name><surname>Goepfert</surname><given-names>H</given-names></name><name><surname>Maor</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Concurrent chemotherapy and radiotherapy for
organ preservation in advanced laryngeal cancer</article-title>. <source>N
Engl J Med</source>.
<year>2003</year>;<volume>349</volume>:<fpage>2091</fpage>-<lpage>2098</lpage>.<pub-id pub-id-type="pmid">14645636</pub-id></mixed-citation></ref><ref id="bibr10-2473974X18761868"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Nambooze</surname><given-names>S</given-names></name><name><surname>Wabwire-Mangen</surname><given-names>F</given-names></name><name><surname>Wabinga</surname><given-names>HR.</given-names></name></person-group>
<article-title>Changing cancer incidence in Kampala, Uganda,
1991-2006</article-title>. <source>Int J Cancer</source>.
<year>2010</year>;<volume>126</volume>:<fpage>1187</fpage>-<lpage>1195</lpage>.<pub-id pub-id-type="pmid">19688826</pub-id></mixed-citation></ref><ref id="bibr11-2473974X18761868"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wabinga</surname><given-names>HR</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Wabwire-Mangen</surname><given-names>F</given-names></name><name><surname>Nambooze</surname><given-names>S.</given-names></name></person-group>
<article-title>Trends in cancer incidence in Kyadondo County, Uganda,
1960-1997</article-title>. <source>Br J Cancer</source>.
<year>2000</year>;<volume>82</volume>:<fpage>1585</fpage>-<lpage>1592</lpage>.<pub-id pub-id-type="pmid">10789729</pub-id></mixed-citation></ref><ref id="bibr12-2473974X18761868"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kakande</surname><given-names>E</given-names></name><name><surname>Byaruhaga</surname><given-names>R</given-names></name><name><surname>Kamulegeya</surname><given-names>A.</given-names></name></person-group>
<article-title>Head and neck squamous cell carcinoma in a Ugandan population: a
descriptive epidemiological study</article-title>. <source>J Afr
Cancer</source>.
<year>2010</year>;<volume>2</volume>:<fpage>219</fpage>-<lpage>225</lpage>.</mixed-citation></ref><ref id="bibr13-2473974X18761868"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mehrotra</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Kapoor</surname><given-names>AK.</given-names></name></person-group>
<article-title>Trends of prevalence and pathological spectrum of head and neck
cancers in North India</article-title>. <source>Indian J Cancer</source>.
<year>2005</year>;<volume>42</volume>:<fpage>89</fpage>-<lpage>93</lpage>.<pub-id pub-id-type="pmid">16141508</pub-id></mixed-citation></ref><ref id="bibr14-2473974X18761868"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Bree</surname><given-names>R</given-names></name><name><surname>Deurloo</surname><given-names>EE</given-names></name><name><surname>Snow</surname><given-names>GB</given-names></name><name><surname>Leemans</surname><given-names>CR.</given-names></name></person-group>
<article-title>Screening for distant metastases in patients with head and neck
cancer</article-title>. <source>Laryngoscope</source>.
<year>2000</year>;<volume>110</volume>:<fpage>397</fpage>-<lpage>401</lpage>.<pub-id pub-id-type="pmid">10718426</pub-id></mixed-citation></ref><ref id="bibr15-2473974X18761868"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Onyango</surname><given-names>JF</given-names></name><name><surname>Macharia</surname><given-names>IM.</given-names></name></person-group>
<article-title>Delays in diagnosis, referral and management of head and neck
cancer presenting at Kenyatta National Hospital, Nairobi</article-title>.
<source>East Afr Med J</source>.
<year>2006</year>;<volume>83</volume>:<fpage>85</fpage>-<lpage>91</lpage>.<pub-id pub-id-type="pmid">16863003</pub-id></mixed-citation></ref><ref id="bibr16-2473974X18761868"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Panje</surname><given-names>WR</given-names></name><name><surname>Namon</surname><given-names>AJ</given-names></name><name><surname>Vokes</surname><given-names>E</given-names></name><name><surname>Haraf</surname><given-names>DJ</given-names></name><name><surname>Weichselbaum</surname><given-names>RR.</given-names></name></person-group>
<article-title>How I do it: head and neck and plastic surgery: surgical
management of the head and neck cancer patient following concomitant
multimodality therapy</article-title>. <source>Laryngoscope</source>.
<year>1995</year>;<volume>105</volume>:<fpage>97</fpage>-<lpage>101</lpage>.<pub-id pub-id-type="pmid">7837923</pub-id></mixed-citation></ref><ref id="bibr17-2473974X18761868"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guha</surname><given-names>N</given-names></name><name><surname>Boffetta</surname><given-names>P</given-names></name><name><surname>W&#x000fc;nsch Filho</surname><given-names>V</given-names></name><etal>et al</etal></person-group>
<article-title>Oral health and risk of squamous cell carcinoma
of the head and neck and esophagus: results of two multicentric case-control
studies</article-title>. <source>Am J Epidemiol</source>.
<year>2007</year>;<volume>166</volume>:<fpage>1159</fpage>-<lpage>1173</lpage>.<pub-id pub-id-type="pmid">17761691</pub-id></mixed-citation></ref><ref id="bibr18-2473974X18761868"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Madan</surname><given-names>M</given-names></name><name><surname>Manjari</surname><given-names>M</given-names></name><name><surname>Bhasin</surname><given-names>TS</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>S.</given-names></name></person-group>
<article-title>Prevalence of head and neck squamous cell carcinoma (HNSCC) in
our population: the clinico-pathological and morphological description of
198 cases</article-title>. <source>Int J Adv Res (Indore)</source>.
<year>2015</year>;<volume>3</volume>:<fpage>827</fpage>-<lpage>833</lpage>.</mixed-citation></ref><ref id="bibr19-2473974X18761868"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olsen</surname><given-names>MH</given-names></name><name><surname>B&#x000f8;je</surname><given-names>CR</given-names></name><name><surname>Kj&#x000e6;r</surname><given-names>TK</given-names></name><etal>et al</etal></person-group>
<article-title>Socioeconomic position and stage at diagnosis of
head and neck cancer&#x02014;a nationwide study from Dahanca</article-title>.
<source>Acta Oncol</source>.
<year>2015</year>;<volume>54</volume>:<fpage>759</fpage>-<lpage>766</lpage>.<pub-id pub-id-type="pmid">25734503</pub-id></mixed-citation></ref><ref id="bibr20-2473974X18761868"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takes</surname><given-names>RP</given-names></name><name><surname>Rinaldo</surname><given-names>A</given-names></name><name><surname>Silver</surname><given-names>CE</given-names></name><etal>et al</etal></person-group>
<article-title>Future of the TNM classification and staging
system in head and neck cancer</article-title>. <source>Head Neck</source>.
<year>2010</year>;<volume>32</volume>:<fpage>1693</fpage>-<lpage>1711</lpage>.<pub-id pub-id-type="pmid">20191627</pub-id></mixed-citation></ref></ref-list></back></article>